Skip to main content
Commentary: Abrocitinib, Malignancy Risk, and S aureus in AD, August 2023
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Commentary: Abrocitinib, Malignancy Risk, and S aureus in AD, August 2023
User login
Username
Password
Reset your password
Concept
Lead
score
Dermatitis
1
0.94
Biologic Therapy
0
0.75
Staphylococcus Aureus Infection
0
0.76
Staphylococcal Infection
0
0.66
Atopic Dermatitis
0
1
Lymphoma
0
0.55
Birth
0
0.08
Skin Rash
0
0.08
Patient Safety
0
0.65
Specialty
Lead
score
Dermatology
1
1
Family Medicine/Primary Care
0
1
Infectious Diseases
0
0.99
Allergy & Clinical Immunology
0
0.72
Pediatrics
0
0.63
Pharmacist
0
0.27
Edit Tags